Preeclampsia, either alone or superimposed on another disorder,is a major cause of maternal and fetal death and the leadingcause of premature delivery worldwide.1 Underappreciated isthe strain that preeclampsia places on the health care resourcesof all nations. This disease increases the need for neonatalintensive care; in addition, early birth may lead to healthproblems later in life. Considerable evidence suggests thatpremature delivery increases the incidence of remote cardiovascularand metabolic health problems, which themselves create enormouseconomic health burdens.2,3 Thus, the ability to predict orprevent preeclampsia or the development of therapy that safelyprolongs . . . [Full Text of this Article]
Source Information
From the Departments of Obstetrics and Gynecology and Medicine, University of Chicago, Chicago (M.D.L.); MedStar Research Institute, Hyattsville, MD (J.G.U.); and the Departments of Medicine and Obstetrics and Gynecology, Georgetown University, Washington, DC (J.G.U.).
This article has been cited by other articles:
Herse, F., Verlohren, S., Wenzel, K., Pape, J., Muller, D. N., Modrow, S., Wallukat, G., Luft, F. C., Redman, C. W.G., Dechend, R.
(2009). Prevalence of Agonistic Autoantibodies Against the Angiotensin II Type 1 Receptor and Soluble fms-Like Tyrosine Kinase 1 in a Gestational Age-Matched Case Study. Hypertension
53: 393-398
[Abstract][Full Text]
Hering, L., Herse, F., Verlohren, S., Park, J.-K., Wellner, M., Qadri, F., Pijnenborg, R., Staff, A. C., Huppertz, B., Muller, D. N., Luft, F. C., Dechend, R.
(2008). Trophoblasts Reduce the Vascular Smooth Muscle Cell Proatherogenic Response. Hypertension
51: 554-559
[Abstract][Full Text]
Previous
